Reliability analysis of a newly developed questionnaire for quality control of follow-up visits in polyiran study

Archives of Iranian Medicine

Volumn 19, Issue 8, 2016, Pages 551-555

  Roshandel, Gholamreza ^a,b   Ostovaneh, Mohammad Reza ^b   Poustchi, Hossein ^b   Malekzadeh, Fatemeh ^b   Sepanlou, Sadaf Ghajarieh ^b   Honarvar, Mohammad Reza ^a   Semnani, Shahryar ^a   Merat, Shahin ^b   Malekzadeh, Reza ^b  

^a GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Follow up visit; PolyIran study; Quality control; Reliability

Indexed keywords

ADULT; ARTICLE; ASSESSMENT OF HUMANS; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; FOLLOW UP; HUMAN; INFORMATION PROCESSING; INTERRATER RELIABILITY; KAPPA STATISTICS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYIRAN QUALITY CONTROL PROGRAM QUESTIONNAIRE; QUALITY CONTROL; SAMPLING; AGED; CARDIOVASCULAR DISEASES; IRAN; MEASUREMENT ACCURACY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; STANDARDS; VALIDATION STUDY;

AGED; CARDIOVASCULAR DISEASES; DATA ACCURACY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IRAN; MALE; MIDDLE AGED; PRAGMATIC CLINICAL TRIALS AS TOPIC; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; SURVEYS AND QUESTIONNAIRES;

EID: 84980332193     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Hartley A, Marshall DC, Salciccioli JD, Sikkel MB, Maruthappu M, Shalhoub J. Trends in Mortality from Ischaemic Heart Disease and Cerebrovascular Disease in Europe: 1980-2009. Circulation. 2016; 133(20): 1916-1926.
2. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001; 104(22): 2746-2753.
3. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 2224-2260.
4. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003; 326(7404): 1419.
5. Pourshams A, Khademi H, Malekshah AF, Islami F, Nouraei M, Sadjadi AR, et al. Cohort Profile: The Golestan Cohort Study-a prospective study of oesophageal cancer in northern Iran. Int J Epidemiol. 2010; 39(1): 52-59.
6. Malekzadeh F, Marshall T, Pourshams A, Gharravi M, Aslani A, Nateghi A, et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (‘polypill’) on cardiovascular risk factors. Int J ClinPract. 2010; 64(9): 1220-1227.
7. Ostovaneh MR, Poustchi H, Hemming K, Marjani H, Pourshams A, Nateghi A, et al. Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial. Eur J Prev Cardiol. 2015; 22(12): 1609-1617.
8. Gassman JJ, Owen WW, Kuntz TE, Martin JP, Amoroso WP. Data quality assurance, monitoring, and reporting. Control Clin Trials. 1995; 16(2 Suppl): 104s-136s.
9. Groom N, Wilson E, Lyn E, Faivre-Finn C. Is pre-trial quality assurance necessary? Experiences of the CONVERT Phase III randomized trial for good performance status patients with limited-stage small-cell lung cancer. Br J Radiol. 2014; 87(1037): 20130653.
10. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986; 1(8476): 307-310.
11. Bautista LE, Vera-Cala LM, Ferrante D, Herrera VM, Miranda JJ, Pichardo R, et al. A ‘polypill’ aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America. Health Aff (Millwood). 2013; 32(1): 155-164.
12. Yusuf S, Pais P, Afzal R, Xavier D, Teo K, Eikelboom J, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009; 373(9672): 1341-1351.
13. Soliman EZ, Mendis S, Dissanayake WP, Somasundaram NP Gunaratne PS, Jayasingne IK, et al. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials. 2011; 12: 3.
14. Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013; 310(1): 918-929.
15. Wald DS, Morris JK, Wald NJ. Randomized Polypill crossover trial in people aged 50 and over. PLoS One. 2012; 7(7): e41297.
16. Rosa C, Campbell A, Kleppinger C, Sampson R, Tyson C, Mamay-Gentilin S. Quality assurance of research protocols conducted in the community: the National Institute on Drug Abuse Clinical Trials Network experience. Clin Trials. 2009; 6(2): 151-161.
17. Lorenzi GM, Braffett BH, Arends VL, Danis RP, Diminick L, Klumpp KA, et al. Quality Control Measures over 30 Years in a Multicenter Clinical Study: Results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. PLoS One. 2015; 10(11): e0141286.
18. Whitney CW, Lind BK, Wahl PW. Quality assurance and quality control in longitudinal studies. Epidemiol Rev. 1998; 20(1): 71-80.
19. Severe JB, Schooler NR, Lee JH, Haas G, Mueser KT, Rosen P, et al. Ensuring data quality in a multicenter clinical trial: remote site data entry, central coordination and feedback. Psychopharmacol Bull. 1989; 25(3): 488-490.
20. Prud’homme GJ, Canner PL, Cutler JA. Quality assurance and monitoring in the Hypertension Prevention Trial. Hypertension Prevention Trial Research Group. Control Clin Trials. 1989; 10(3 Suppl): 84s-94s.
21. Chalmers TC, Smith Jr. H, Blackburn B, Silverman B, Schroeder B, Reitman D, et al. A method for assessing the quality of a randomized control trial. Control Clin Trials. 1981; 2(1): 31-49.
22. Marinez YN, McMahan CA, Barnwell GM, Wigodsky HS. Ensuring data quality in medical research through an integrated data management system. Stat Med. 1984; 3(2): 101-111.
23. Admon AJ, Bazile J, Makungwa H, Chingoli MA, Hirschhorn LR, Peckarsky M, et al. Assessing and improving data quality from community health workers: a successful intervention in Neno, Malawi. Public Health Action. 2013; 3(1): 56-59.
24. Hedt-Gauthier BL, Tenthani L, Mitchell S, Chimbwandira FM, Makombe S, Chirwa Z, et al. Improving data quality and supervision of antiretroviral therapy sites in Malawi: an application of Lot Quality Assurance Sampling. BMC Health Serv Res. 2012; 12: 196.
25. Fukushima M. Quality control in clinical trials [in Japanese]. Gan To Kagaku Ryoho. 1996; 23(2): 172-182.